| Document |
Document Title |
|
WO/2024/064779A1 |
The present invention provides a compound of Formula I: wherein R is H or; R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or C...
|
|
WO/2024/037644A1 |
The present invention provides a polyethylene glycol (PEG)-modified glucocorticoid medicament and use thereof, including, but not limited to, asthma, chronic obstructive pulmonary disease, bronchitis, rhinitis, and the like, and relates ...
|
|
WO/2024/020164A2 |
The present disclosure describes glucocorticoid agonist compounds, their conjugates with binding proteins, pharmaceutical compositions thereof, as well as methods and uses for treating diseases or conditions, such as autoimmune or inflam...
|
|
WO/2023/241877A1 |
The present invention relates to a process for the preparation of a budesonide intermediate, in particular the compound of formula (I).
|
|
WO/2023/245106A1 |
The present disclosure provides anti-CD19 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
|
|
WO/2023/235738A1 |
The present disclosure provides human interleukin 4 receptor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of inflammatory diseases, such as type 2 inflammatory diseases.
|
|
WO/2023/220549A1 |
The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.
|
|
WO/2023/219265A1 |
The present invention relates to a preparation method for a plasma-treated ergosterol reactant, a reactant prepared by the preparation method, and a compound isolated therefrom and use thereof. The plasma-treated ergosterol reactant prep...
|
|
WO/2022/232602A9 |
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. These compounds are conjugates of glucocorticoids with rho-kinase inhibitors. Also provided herein are methods of t...
|
|
WO/2023/186072A1 |
The present disclosure relates to a ligand-drug conjugate of a novel structure or a pharmaceutically acceptable salt thereof. Specifically, the present disclosure provides a ligand-drug conjugate of a structural general formula of Pc-(L-...
|
|
WO/2023/151623A1 |
A preparation method for a natural bufogenin compound, comprising: taking cheap and easily available commercial steroid skeleton materials such as androstenedione 4-AD or 3β-hydroxyl-5β-androstane-17-ketone; performing simple conversio...
|
|
WO/2023/143399A1 |
Disclosed in the present invention are a steroid compound, and a preparation method therefor and an application thereof. The steroid compound may have a structure as shown in formula XXI, etc. The compound of the present invention has SR...
|
|
WO/2023/143398A1 |
Disclosed in the present invention are a steroid and a preparation method therefor and an application thereof. The steroid may have a structure as shown in formula II. The compound of the present invention has SREBP pathway inhibitory ac...
|
|
WO/2023/118484A1 |
A drug on the basis of 7,19-epoxy steroids, containing a compound of the general formula (I) or a physiologically acceptable salt thereof, wherein R1 = H; methyl, aryl-CH2-, Rx-C(=O)- or Rx-O-C(=O)-; or R1O is dispensed with if there is ...
|
|
WO/2023/115220A1 |
A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol; tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexac...
|
|
WO/2023/040793A1 |
Provided are an anti-inflammatory compound and the use thereof. Specifically, provided are the compound or a tautomer, a mesomer, a racemate, an enantiomer and a diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically a...
|
|
WO/2023/025248A1 |
The present invention relates to a steroid compound and a conjugate thereof, and specifically relates to a compound and a conjugate thereof, or a tautomer, a mesomer, a racemate, an enantiomer and a diastereoisomer thereof, or a mixture ...
|
|
WO/2023/016817A1 |
The present invention is directed to a process for the preparation of ∆9,11 steroids by deoxygenation of 9,11-epoxy steroids using HI. The disclosed process selectively forms ∆9,11 steroids such as Vamorolone and can also be used for...
|
|
WO/2023/011512A1 |
The present invention provides crystal forms of the compound Kuding saponin A, and a pharmaceutical composition and a use thereof. The crystal forms comprise crystal forms A, B, C, D, E, G, J, K and L. Characteristic peaks in the X-ray p...
|
|
WO/2023/001901A1 |
The present invention relates to a new process for the preparation of budesonide 21- phosphate and its disodium salt.
|
|
WO/2023/284782A1 |
A method for screening a compound used for treating or preventing mHTT-related neurodegenerative diseases, target protein used for screening, and a corresponding compound.
|
|
WO/2023/288123A1 |
The present application relates to methods and novel intermediates useful in the preparation of a compound of formula 100 (Compound 100).
|
|
WO/2023/275052A1 |
The present invention provides compounds of Formula (I), or a solvate, a tautomer, a stereoisomer or a salt thereof, for use in therapy, such as in the treatment of cancer. Also provided are compositions comprising the compounds of the i...
|
|
WO/2022/268176A1 |
A compound as represented by formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof, a preparation method therefor, and the use thereof in the treatment of tumors, inflammatory diseases or autoi...
|
|
WO/2022/271147A1 |
Disclosed are anti-fungal compositions prepared from non-woody plants of the genus Hesperaloe and processes for preparing the same. The anti-fungal compositions preferably comprise at least one saponin. In certain instances, the process ...
|
|
WO/2022/246907A1 |
Provided are a compound containing a 2,4-thiazole ring, a preparation method therefor, and an application thereof. The compound is represented by formula (X), where A is pyrazolopyrimidine or indole; Z is absent or is a carbonyl group; X...
|
|
WO/2022/238572A1 |
The invention relates to a synthesis of cholesterol; a ring opening step of the compound of formula (I) and subsequent activation and reduction step yielding cholesterol. The inventions relates also to intermediates achieved during said ...
|
|
WO/2022/204100A1 |
The present invention provides a compound of Formula I: wherein R is hydrogen, -P(=O)(OH)2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treat...
|
|
WO/2022/204108A1 |
The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH...
|
|
WO/2022/204099A1 |
The present invention provides a compound of Formula I: (I) wherein R1 is H, halogen, C1-C3 alkyl, or C1-C3 alkoxy; R2 is H or halogen; and X is O, OCH2, or CH2, or a pharmaceutically acceptable salt thereof, wherein the compound of Form...
|
|
WO/2022/171101A1 |
The present application relates to a steroid conjugate, and in particular, to a compound or a tautomer, a mesomer, a racemate, an enantiomer, and a diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt...
|
|
WO/2022/166779A1 |
A drug conjugate of a glucocorticoid receptor agonist, and an application thereof in medicine. Specifically, the present invention relates to an antibody-drug conjugate as represented by formula (I): Ab-(L-D)k (I), wherein Ab is an antib...
|
|
WO/2022/170364A1 |
Disclosed herein are a modified guayule resin product and related processes for preparing the modified guayule resin product. The modified guayule resin product comprises a mixture of argentatins having at least one functional group, whe...
|
|
WO/2022/155614A1 |
Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant ...
|
|
WO/2022/135332A1 |
A steroid conjugate. Specifically, the present invention relates to a compound or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method theref...
|
|
WO/2022/135331A1 |
A stable liquid pharmaceutical composition containing a Kuding saponin compound, containing a therapeutically effective amount of Kuding saponin compound, a buffer effective amount of buffer solution having a pH of 6.5-7.5, and a pharmac...
|
|
WO/2022/133477A1 |
Disclosed herein are a modified guayule resin product and related processes for preparing the modified guayule resin product. The modified guayule resin product comprises a mixture of argentatins having at least one functional group, whe...
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/100722A1 |
A 5,6-epoxy sterol compound intermediate, and a preparation method therefor and an application thereof. The intermediate has a chemical structure represented by formula I, wherein R is selected from -CH 2OCOR 1 or -CH＝CH-CO(O)R 1, and ...
|
|
WO/2021/258053A1 |
Disclosed are soluble extractives prepared from non-woody plants of the genus Hesperaloe and processes for preparing the same. The extracts preferably comprise at least one saponin. In certain instances, the process includes providing bi...
|
|
WO/2021/203938A1 |
The present invention relates to a compound for treating gout, a preparation method therefor and the use thereof. The compound is as represented by formula I. Disclosed in the present invention are a method for preparing the compound and...
|
|
WO/2021/191366A1 |
The present invention relates to salts of budesonide 21-phosphate with β2 adrenergic agonists, preferably with formoterol, pharmaceutical compositions containing the same and the use thereof in the treatment of respiratory inflammatory ...
|
|
WO/2021/103170A1 |
The present invention provides a non-bitter-taste bitter gourd triterpenoid composition for inhibiting liver gluconeogenesis, the active ingredients thereof consisting primarily of Charantoside C and Momordicoside F1, the proportion by m...
|
|
WO/2021/097046A1 |
The disclosure relates to anti-cancer compounds which are anti-cancer PARP inhibitors of formula Al, A2, A3 or A4 conjugated by a linker to a steroid, whereby the steroid targets the conjugate to the nucleus, as well as to methods for th...
|
|
WO/2021/068992A1 |
Disclosed in the present invention is a method for producing biogas from waste liquid after diosgenin is extracted using aluminum chloride. Specifically, in a fermentation vessel, an anaerobic sludge having a volatile solids ratio of 1-3...
|
|
WO/2021/068991A1 |
A method for preparing diosgenin by ternary two-phase AlCl3 hydrolysis. Dried yam powder is placed into a reaction vessel, and then a ternary, two-phase solution consisting of an aqueous aluminum chloride solution, ethanol, and petroleum...
|
|
WO/2021/023751A1 |
The present invention relates to esters of Montelukast with corticosteroids, preferably with des-ciclesonide, triamcinolone, budesonide or flunisolide, pharmaceutical compositions containing the same and the use thereof in the treatment ...
|
|
WO/2021/014348A1 |
The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the t...
|
|
WO/2021/016191A1 |
Disclosed herein are compounds of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidan...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
